Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.

[1]  J. Desenclos,et al.  Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. , 1998, The Pediatric infectious disease journal.

[2]  R. Dagan,et al.  Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. , 1997, The Pediatric infectious disease journal.

[3]  S. Mboup,et al.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. , 1997, Vaccine.

[4]  F. Mooi,et al.  Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. , 1997, Emerging infectious diseases.

[5]  J. Cherry,et al.  Historical review of pertussis and the classical vaccine. , 1996, The Journal of infectious diseases.

[6]  S. Halperin,et al.  Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. , 1996, Vaccine.

[7]  H. Hallander,et al.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.

[8]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[9]  M. Gahr,et al.  Efficacy of acellular pertussis vaccine in early childhood after household exposure. , 1996, JAMA.

[10]  M. Pichichero,et al.  Comparison of 13 acellular pertussis vaccines: adverse reactions. , 1993, Pediatrics.

[11]  H. Fineberg,et al.  Acute encephalopathy and chronic neurological damage after pertussis vaccine. , 1993, Vaccine.

[12]  S. Plotkin,et al.  Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants , 1991 .

[13]  S. Wassilak,et al.  The epidemiological situation of pertussis in the Federal Republic of Germany. , 1991, Developments in biological standardization.

[14]  E. Mortimer.  Pertussis and its prevention: a family affair. , 1990, The Journal of infectious diseases.

[15]  K. Reisinger,et al.  Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. , 1990, American journal of diseases of children.

[16]  M. Granström,et al.  Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. , 1989, Pediatrics.

[17]  A. Balfour,et al.  Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test. , 1988, Journal of medical microbiology.

[18]  P. Hung,et al.  Clinical and serologic responses to acellular pertussis vaccine in infants and young children. , 1987, American journal of diseases of children.

[19]  V. Romanus,et al.  Pertussis in Sweden after the cessation of general immunization in 1979. , 1987, The Pediatric infectious disease journal.

[20]  A. Saah,et al.  Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. , 1987, JAMA.

[21]  K. Edwards,et al.  Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components. , 1986, American journal of diseases of children.

[22]  R. Barkin,et al.  DTP reactions and serologic response with a reduced dose schedule. , 1984, The Journal of pediatrics.

[23]  T. Anglin.  Physician management of sexually abused children and adolescents. , 1984, Current problems in pediatrics.

[24]  V. Seagroatt,et al.  A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. , 1983, Journal of biological standardization.

[25]  D. Cassels,et al.  Effect of the patent ductus arteriosus on the pulmonary blood flow, blood volume, heart rate, blood pressure, arterial blood gases and pH. , 1950, Pediatrics.